InsiderTrades.com logo
A.I. Pioneer Issues Urgent Warning to Americans
From TradeSmith   |   Ad
With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.
Click here to see Louis' new video for yourself.
Marc A. Becker net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Marc Becker Biography and Net Worth

CFO of Concert Pharmaceuticals
Mr. Marc Becker has served as our Chief Financial Officer since January 2018. Prior to joining Concert, Mr. Becker served as Senior Vice President and Chief Financial Officer at CRISPR Therapeutics from February 2016 to September 2017. Prior to joining CRISPR Therapeutics, Mr. Becker served as Chief Financial Officer and Senior Vice President of rEVO Biologics, a biopharmaceutical company, from January 2012 to February 2016. Before rEVO, Mr. Becker spent 10 years at Genzyme Corporation, most recently serving as Finance Director for the UK and Ireland before returning to the United States to become the Vice President of Finance for Genzyme’s Renal and Endocrine business. He also serves on the Board of Directors of Food for Free, a non-profit organization in Cambridge, MA. Mr. Becker began his career in auditing and commercial lending for financial services firms, KPMG and BankBoston. Mr. Becker holds a BS from the University of Massachusetts, an MBA from Babson College and was licensed as a CPA.

What is Marc A. Becker's net worth?

The estimated net worth of Marc A. Becker is at least $536,240.79 as of August 16th, 2021. Mr. Becker owns 64,067 shares of Concert Pharmaceuticals stock worth more than $536,241 as of April 18th. This net worth approximation does not reflect any other investments that Mr. Becker may own. Learn More about Marc A. Becker's net worth.

How do I contact Marc A. Becker?

The corporate mailing address for Mr. Becker and other Concert Pharmaceuticals executives is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. Concert Pharmaceuticals can also be reached via phone at (781) 860-0045 and via email at [email protected]. Learn More on Marc A. Becker's contact information.

Has Marc A. Becker been buying or selling shares of Concert Pharmaceuticals?

Marc A. Becker has not been actively trading shares of Concert Pharmaceuticals during the past quarter. Most recently, Marc A. Becker sold 7,304 shares of the business's stock in a transaction on Monday, August 16th. The shares were sold at an average price of $3.28, for a transaction totalling $23,957.12. Following the completion of the sale, the chief financial officer now directly owns 64,067 shares of the company's stock, valued at $210,139.76. Learn More on Marc A. Becker's trading history.

Who are Concert Pharmaceuticals' active insiders?

Concert Pharmaceuticals' insider roster includes Marc Becker (CFO), James Cassella (Insider), Jeffrey Munsie (Insider), Nancy Stuart (COO), and Roger Tung (CEO). Learn More on Concert Pharmaceuticals' active insiders.

Marc A. Becker Insider Trading History at Concert Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2021Sell7,304$3.28$23,957.1264,067View SEC Filing Icon  
See Full Table

Marc A. Becker Buying and Selling Activity at Concert Pharmaceuticals

This chart shows Marc A Becker's buying and selling at Concert Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Concert Pharmaceuticals Company Overview

Concert Pharmaceuticals logo
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $8.37
Low: $8.37
High: $8.37

50 Day Range

MA: $8.37
Low: $8.33
High: $8.40

2 Week Range

Now: $8.37
Low: $2.66
High: $8.55

Volume

N/A

Average Volume

2,970,800 shs

Market Capitalization

$401.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52
A.I. Pioneer Issues Urgent Warning to Americans
From TradeSmith   |   Ad
With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.
Click here to see Louis' new video for yourself.